Trial Profile
Regeneration in Cervical Degenerative Myelopathy - a multi-centre, double-blind, randomised, placebo controlled trial assessing the efficacy of Ibudilast as an adjuvant treatment to decompressive surgery for degenerative cervical myelopathy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Ibudilast (Primary)
- Indications Spinal cord disorders
- Focus Therapeutic Use
- Acronyms RECEDE Myelopathy
- 08 Mar 2023 The patient recruitment is expected to be completed by 28 Sep 2025.
- 24 Dec 2021 Status changed from not yet recruiting to recruiting.
- 11 Nov 2020 Planned number of patients changed from 362 to 400.